Application
Carmofur has been used as an inhibitor of acid ceramidase to study its effects on glucosylsphingosine (GlcSph) production in human embryonic kidney 293T (HEK293T) cells. It has also been used as an inhibitor of acid ceramidase to study its effects on acid‐mediated hydrolysis of ceramide which kicks-in consumption and the generation of sphingosine .
Biochem/physiol Actions
Carmofur acts as an inhibitor of fatty acid amide hydrolase (FAAH), N-acylethanolamine acid amidase (NAAA) and acid ceramidase (ASAH1). Carmofur has a therapeutic activity against colorectal and cervical cancer. It can inhibit the severe acute respiratory syndrome (SARS)-CoV-2 main protease (Mpro) in vitro.
Carmofur is a derivative of fluorouracil, an antimetabolite used as an antineoplastic agent.
Carmofur is an antineoplastic agent and a flurorouracil analog.
| Quality Segment | 100 |
| assay | ≥98% (HPLC) |
| form | powder |
| color | white to off-white |
| solubility | DMSO: >15 mg/mL |
| storage temp. | 2-8°C |
| SMILES string | CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O |
| InChI | 1S/C11H16FN3O3/c1-2-3-4-5-6-13-10(17)15-7-8(12)9(16)14-11(15)18/h7H,2-6H2,1H3,(H,13,17)(H,14,16,18) |
| InChI key | AOCCBINRVIKJHY-UHFFFAOYSA-N |
